Once in the bloodstream, cibinetide binds this receptor on immune cells (especially myeloid cells like macrophages and microglia), endothelial cells, and other stressed tissues, triggering intracellular signaling (e.g., JAK/STAT, PI3K/Akt, and inhibition of NF-B p65) that dampens innate immune overactivation, suppresses production and systemic release of pro-inflammatory cytokines (TNF-, IL-1, IL-6, IL-12/IL-23), reduces chemokine-driven cell infiltration, lowers oxidative stress and nitric oxide overproduction, and promotes anti-inflammatory shifts and cell survival
Critical responses included local inflammation and oxidative stress, leading to microbiota dysbiosis, metabolic, hepatic, and reproductive disorders, and diseases exacerbation
BPC-157 is not licensed as a medicine in the UAE or by the FDA, the human surgical evidence is still preliminary, and any clinical conversation about it can only happen on an individual basis with appropriate medical supervision and through proper channels
31 , e23e26 (2024)